<i>In Situ</i>-Forming Gels for Ophthalmic Drug Delivery

Kumar, Sandeep; Haglund, Bert O.; Himmelstein, Kenneth J.

doi:10.1089/jop.1994.10.47

Cited by 114 publications

(51 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6) In addition, the topically applied drugs could enter the systemic circulation via conjunctiva and nasal mucosa, 7) which may result in some undesirable side effects. 8) Ophthalmic ointment formulations demonstrated substantially improvement in drug bioavailability when compared with their eye drops counterparts. However, they suffered from some disadvantages that include sticky sensation, blurred vision and induced reflex blinking which also caused patient non-compliance.…”

mentioning

confidence: 99%

Potential Use of Niosomal Hydrogel as an Ocular Delivery System for Atenolol

Hashim

El-Dahan

Yusif

et al. 2014

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Niosomes have been reported as possible approach to improve the low corneal penetration and bioavailability characteristics for many drugs. The purpose of this study was to prepare and characterize an effective ocular niosomal hydrogel containing 0.5% (w/v) atenolol which is β1 adrenoceptor blocker for treatment of glaucoma. Thin film hydration method was used for the preparation of niosomes using Span 60 and cholesterol at different molar ratios. Niosomes were characterized using laser diffraction particle size analyzer, transmission electron microscopy, and differential scanning calorimetry. The results showed that higher entrapment efficiency (80.7% 1.2) was obtained from niosomes prepared using Span 60/cholesterol at a 2 : 1 molar ratio. Stability study revealed that a fairly high retention of atenolol inside vesicles (83.1% 2.35) up to a period of 3 months at 4°C. It was found that niosomal hydrogel formulation using carbopol 934P significantly exhibited sustained in vitro release of the drug compared with free drug solution and other polymeric hydrogels. The intraocular pressure (IOP) lowering activity of selected atenolol formulations was determined and compared with that of atenolol solution. It is worth noting that niosomal hydrogel formulation was found to show the most significant prolonged decrease in IOP, suggesting that niosomal hydrogel could be a promising delivery system for atenolol.

show abstract

mentioning

confidence: 99%

Potential Use of Niosomal Hydrogel as an Ocular Delivery System for Atenolol

Hashim

El-Dahan

Yusif

et al. 2014

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…Among the compositions studied, a solution containing 1.5% MC and 0.3 % carbopol was found to have low viscosity, and formed a strong gel under simulated physiological conditions 46 .…”

Section: Issn: 0975-8232mentioning

confidence: 97%

Untitled

2012

IJPSR

View full text Add to dashboard Cite

Topical administration of a drug in the conjunctival cul-de-sac is the treatment of choice for diseases of the anterior segment of eye. Development of ophthalmic drug delivery systems has always been challenging because of the drawbacks with this route, like non-productive absorption, drainage, induced lacrimation, tear turn over, impermeability of drugs to cornea. New approaches have been investigated for delivery of drugs to the eye by means of polymeric delivery of ophthalmic drugs to the pre-and intra ocular tissues, have been attempted to increase the bioavailability and the duration of therapeutic action of ocular drug. Certain new approaches to increase the ocular bioavailability, duration of the drug action and to reduce the undesirable side effects are by using drug carriers that regulate pre-corneal drug loss and improve the corneal contact time. Many of these systems prolong ocular bioavailability but do not control drug penetration through the cornea. Consequently, the drug concentration at the site of action might remain inadequate. Therefore, it is necessary to develop safer, efficacious and more acceptable ocular therapeutic system. The ocular bioavailability of the drugs can be improved by prolonging their residence time in the cul-de-sac and by increasing their corneal permeability. There are various new dosage forms like in-situ gel, collagen shield, etc.

show abstract

“…unnoticed expulsion from the eye, membrane ruptures etc.). A number of ocular inserts were prepared utilizing different techniques to make soluble, erodible, nonerodible, and hydrogel inserts [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] .…”

Section: Ocular Insertsmentioning

confidence: 99%

Occular Drug Delivery System: An Overview

Ara¹,

Bundela²,

Nimb³

et al. 2017

Curr. Res. Pharm. Sci.

View full text Add to dashboard Cite

Delivery of drugs to the targeted ocular tissues is restricted by various precorneal, dynamic and static ocular barriers. Also, therapeutic drug levels are not maintained for longer duration in target tissues. In the past two decades, ocular drug delivery research acceleratedly advanced towards developing a novel, safe and patient compliant formulation and drug delivery devices/techniques, which may surpass these barriers and maintain drug levels in tissues. Anterior segment drug delivery advances are witnessed by modulation of conventional topical solutions with permeation and viscosity enhancers. Also, it includes development of conventional topical formulations such as suspensions, emulsions and ointments. On the other hand, for posterior ocular delivery, research has been immensely focused towards development of drug releasing devices and nanoformulations for treating chronic vitreoretinal diseases. These occuserts formulations may help to surpass ocular barriers and associated side effects with conventional topical drops. Also, these novel devices and/or formulations are easy to formulate, no/negligibly irritating, possess high precorneal residence time, sustain the drug release, and enhance ocular bioavailability of therapeutics. An update of current research advancement in ocular drug delivery necessitates and helps drug delivery scientists to modulate their think process and develop novel and safe drug delivery strategies.

show abstract

In Situ-Forming Gels for Ophthalmic Drug Delivery

Cited by 114 publications

References 11 publications

Potential Use of Niosomal Hydrogel as an Ocular Delivery System for Atenolol

Potential Use of Niosomal Hydrogel as an Ocular Delivery System for Atenolol

Untitled

Occular Drug Delivery System: An Overview

Contact Info

Product

Resources

About